Replies to post #135170 on Enzolytics Inc (ENZC)

[Mistafixit]

I believe enzc will have the upper hand with clone 3 targeting conserved sites. Astrizenica is showing only %77 efficacy from what I see. That will most likely drop as the virus mutates. People are starting to wakeup to MABs due to successful treatments looking at Regeneron. Most others are based of the immune system of a mouse. Enzc is based of a human so in theory should be safer. Plenty of market space for multiple treatments. Hopefully %95+ efficacy with enzc in a safe delivery system to be a leader in the space. Best of luck!

[Catpole]

This is a 6 month preventive application where as ENZC MABs will kill the virus and also keep it from mutating. Both are needed!